Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8050829 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL8040037 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL10705520 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL19788605 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL6252053 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL14867340 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL8183533 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL2807289 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL6249176 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 | |
| SCHEMBL7904533 | 0.79 | USP2 (0.38) | SMN1; SMN2PRKCAALDH1A1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865779-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2014-10-21 | — | — | US | disclosed |
| US-20100168422-A1 | METHODS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HEXAHYDROFURO [2,3-B]FURAN-3-OL | CLINTON HEALTH ACCESS INITIATIVE, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168422-A1 | METHODS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HEXAHYDROFURO [2,3-B]FURAN-3-OL | FDPS, DHFR, AKR7A2 | SMN1; SMN2 2937/4885PRKCA 4041/4885ALDH1A1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.